Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Genetic Markers of Helicobacter pylori Antibiotic Resistance in Moscow

Natalia Bodunova
* ,
Larisa Tsapkova
* ,
Vera Polyakova
,
Irina Baratova
ORCID logo ,
Konstantin Rumyantsev
,
Natalia Dekhnich
,
Karina Nikolskaya
,
Margarita Chebotareva
,
Irina Voynovan
,
Elena Parfenchikova
,
Galina Pronina
,
Ekaterina Chernikova
,
Dmitry Bordin
ORCID logo
Version 1 : Received: 11 April 2024 / Approved: 11 April 2024 / Online: 12 April 2024 (03:53:47 CEST)

How to cite: Bodunova, N.; Tsapkova, L.; Polyakova, V.; Baratova, I.; Rumyantsev, K.; Dekhnich, N.; Nikolskaya, K.; Chebotareva, M.; Voynovan, I.; Parfenchikova, E.; Pronina, G.; Chernikova, E.; Bordin, D. Genetic Markers of Helicobacter pylori Antibiotic Resistance in Moscow. Preprints 2024, 2024040812. https://doi.org/10.20944/preprints202404.0812.v1 Bodunova, N.; Tsapkova, L.; Polyakova, V.; Baratova, I.; Rumyantsev, K.; Dekhnich, N.; Nikolskaya, K.; Chebotareva, M.; Voynovan, I.; Parfenchikova, E.; Pronina, G.; Chernikova, E.; Bordin, D. Genetic Markers of Helicobacter pylori Antibiotic Resistance in Moscow. Preprints 2024, 2024040812. https://doi.org/10.20944/preprints202404.0812.v1

Abstract

The Maastricht VI/Florence consensus recommends, as one of the measures to enhance the efficacy of Helicobacter pylori (H. pylori) infection eradication, a personalized treatment approach involving the selection of an antimicrobial agent based on the pre-determined resistance of H. pylori. To meet the need to develop test systems for personalized drug selection, we conducted a study of H. pylori molecular resistance in Moscow using a self-developed Sanger sequencing test platform. We validated our test system on 25 pure culture samples of H. pylori with known resistance. Sensitivity and specificity for detecting resistance to clarithromycin was 100%, and to levofloxacin - 93% and 92%, respectively. Then we tested our platform on 112 H. pylori -positive patients who had not previously received proton pump inhibitors (PPI) or antibacterial drugs. Mutations indicating resistance to clarithromycin were found in 27 (24%) samples, and to levofloxacin in 26 (23%) samples. Double resistance was observed in 16 (14%) samples. The most common mutations leading to clarithromycin resistance were 2143G and 2142G, to levofloxacin resistance – 261A and 271A in the gyrA gene, which account for 69% of all identified genetic determinants in levofloxacin-resistant bacteria. Thus, a personalized approach to the selection of H. pylori eradication therapy based on the detection of bacterial resistance before prescribing first-line therapy could help avoid the prescription of ineffective H. pylori eradication therapies and, overall, contribute to the control of antibiotic resistance of H. pylori.

Keywords

Helicobacter pylori; antibiotic resistance; methods for determining H. pylori resistance; molecular genetic diagnostics; phenotypic methods for determining antibiotic resistance; geographical distribution of H. pylori antibiotic resistance

Subject

Medicine and Pharmacology, Gastroenterology and Hepatology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.